Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone Receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Early research (Phase 1)Looking for participantsNCT07454642
What this trial is testing

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Who this might be right for
Vulvar AdenocarcinomaPDAC - Pancreatic Ductal AdenocarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd 174
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Large-scale testing (Phase 3)Ended earlyNCT00267553
What this trial is testing

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasms, Hormone-Dependent
Intarcia Therapeutics 200
Post-approval studies (Phase 4)Ended earlyNCT00241046
What this trial is testing

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 13
Not applicableStudy completedNCT03280303
What this trial is testing

Palbociclib in Real World Practice

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Pfizer 1,285
Testing effectiveness (Phase 2)Ended earlyNCT05176080
What this trial is testing

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Study completedNCT02668666
What this trial is testing

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastEstrogen Receptor Positive Breast Cancer+2 more
Oana Danciu, MD 49
Early research (Phase 1)Looking for participantsNCT06120283
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorAdvanced Breast CancerMetastatic Breast Cancer+5 more
BeOne Medicines 433
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Testing effectiveness (Phase 2)Study completedNCT02894398
What this trial is testing

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Who this might be right for
Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
iOMEDICO AG 388
Early research (Phase 1)Not Yet RecruitingNCT07590583
What this trial is testing

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial

Who this might be right for
Advanced Hormone Receptor-Positive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more
City of Hope Medical Center 20
Not applicableNot Yet RecruitingNCT06729099
What this trial is testing

Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients

Who this might be right for
Breast Cancer, Estrogen Receptor-Positive
Assiut University 128
Large-scale testing (Phase 3)Study completedNCT02767661
What this trial is testing

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sun Yat-sen University 263
Testing effectiveness (Phase 2)Ended earlyNCT02258464
What this trial is testing

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 99
Testing effectiveness (Phase 2)Ended earlyNCT00905021
What this trial is testing

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Baylor Breast Care Center 4
Testing effectiveness (Phase 2)Study completedNCT00057941
What this trial is testing

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor-positive Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 148
Testing effectiveness (Phase 2)WithdrawnNCT02115594
What this trial is testing

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Syndax Pharmaceuticals
Next Page